These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
Researchers involved in the OPTIMISTIC trial have published a scientific paper that identifies genetic factors that influence the severity of myotonic dystrophy type 1.Read more
AMO Pharma has announced results from its ongoing phase II study investigating tideglusib as a treatment in individuals with myotonic dystrophy.
Two research studies using data from the UK Myotonic Dystrophy Patient Registry have been published recently. The registry is jointly supported by Muscular Dystrophy UK and MDSG.
As part of the EU-funded PREFER project, we are helping to organise a focus group for people with myotonic dystrophy and their caregivers.
The US Food and Drug Administration (FDA) has granted Fast Track designation to AMO-02 (also known as tideglusib) for the treatment of congenital myotonic dystrophy.
MDUK-funded clinical fellow, Dr Mark Hamilton, has found that a particular blood test might be useful for flagging potential heart issues in people with myotonic dystrophy type 1.
The purpose of this study is to investigate the safety of a drug called tideglusib.
We are pleased to announce that we are investing over £470,000 into three new myotonic dystrophy research projects that came out of our grant round.
We are delighted to announce that we are investing approximately £1.7 million into 10 new research projects that came out of our grant rounds.
AMO Pharma have today announced the initiation of a phase 2 clinical study testing tideglusib (AMO-02) in people with myotonic dystrophy type 1.
Prof Brook and colleagues are hoping to develop a drug that would target most features of myotonic dystrophy type 1 (DM1)